Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been given an average rating of “Moderate Buy” by the seven brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $9.00.

Several research firms recently weighed in on PYXS. Royal Bank of Canada reiterated an “outperform” rating and issued a $8.00 target price (down previously from $10.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. Stephens began coverage on Pyxis Oncology in a report on Friday, November 8th. They set an “overweight” rating and a $13.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $5.00 price objective (down from $7.00) on shares of Pyxis Oncology in a research report on Friday, December 20th. Finally, William Blair cut Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st.

Insider Buying and Selling at Pyxis Oncology

In other news, CFO Pamela Ann Connealy bought 88,850 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was bought at an average price of $1.96 per share, for a total transaction of $174,146.00. Following the completion of the purchase, the chief financial officer now owns 1,199,143 shares of the company’s stock, valued at approximately $2,350,320.28. The trade was a 8.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 9.80% of the company’s stock.

Institutional Investors Weigh In On Pyxis Oncology

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Millennium Management LLC boosted its stake in Pyxis Oncology by 125.3% in the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock worth $4,425,000 after purchasing an additional 743,499 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Pyxis Oncology in the third quarter valued at about $1,405,000. State Street Corp lifted its position in Pyxis Oncology by 28.0% during the 3rd quarter. State Street Corp now owns 951,251 shares of the company’s stock worth $3,491,000 after buying an additional 208,344 shares in the last quarter. abrdn plc grew its holdings in Pyxis Oncology by 28.9% during the 3rd quarter. abrdn plc now owns 913,045 shares of the company’s stock worth $3,351,000 after acquiring an additional 204,742 shares during the last quarter. Finally, LMR Partners LLP acquired a new stake in Pyxis Oncology in the 3rd quarter valued at about $294,000. 39.09% of the stock is owned by institutional investors and hedge funds.

Pyxis Oncology Price Performance

NASDAQ PYXS opened at $1.51 on Friday. The company’s fifty day moving average is $1.63 and its two-hundred day moving average is $2.90. Pyxis Oncology has a 52-week low of $1.39 and a 52-week high of $6.85. The firm has a market capitalization of $89.80 million, a price-to-earnings ratio of -1.47 and a beta of 1.06.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.